[Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina].
The efficiency of retinalamin was studied in 33 patients, aged 4 to 7, with 5 types of retinal abiotrophy. The experimental group comprised children with retinal abiotrophy of Franceschetti type (36%) and mixed type (39%). The pathological process was stabilized during 18 months in all cases of developed disease. The visual acuity improved in 82% of patients after treatment by retinalamin; visual fields enlarged and central scotomas reduced in 54% of cases. Parameters of elctroretinography improved in 37% of cases.
Khvatova
A V
AV
Khlebnikova
O V
OV
Meshkova
G I
GI
Tarasenkov
A O
AO
Shchuvatova
E L
EL
Stromova
O V
OV
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D001691:Biological Therapy / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D004596:Electroretinography; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D009915:Orbit; D010455:Peptides / Q000008:administration & dosage*; D012160:Retina / Q000187:drug effects / Q000503:physiopathology; D012174:Retinitis Pigmentosa / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014792:Visual Acuity; D014794:Visual Fields
D000276:Adjuvants, Immunologic; D010455:Peptides